Beryl Drugs Ltd
₹24.92
-0.10 (0.40%)
Fri, 23 Oct 2026, 00:54 pm
Health Technology
Pharmaceuticals: Other
24.5KBeryl Drugs Enterprise Value (EV)
| Particulars | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 317 | 185 | 118.44 | 100 | 36.97 | 69.53 | 218.53 | 98.03 | 63.04 | 6.12 | 7.18 | 38.62 | 13.99 | 0 | 8.05 | 19.35 | 18.45 |
| Price to book ratio | 0.87 | 0.84 | 1.70 | 1.51 | 2.34 | 2.93 | 2.92 | 2.48 | 1.25 | 0.91 | 0.56 | 0.24 | 0.42 | 0.73 | 0.76 | 1.67 | 1.12 |
| Price to sales ratio | 0.69 | 0.69 | 1.31 | 0.95 | 1 | 1.29 | 1.42 | 1.26 | 0.67 | 0.40 | 0.33 | 0.14 | 0.24 | 0.37 | 0.23 | 0.56 | 0.51 |
| Price to cash flow ratio | 22.14 | 15.92 | 126.60 | 14.28 | 22.50 | 0 | 71.31 | 0 | 25.55 | 0 | 1.21 | 0 | 0 | 0 | 3.15 | 41.70 | 5.07 |
| Enterprise value | 5.62Cr | 5.42Cr | 10.68Cr | 9.46Cr | 14.5Cr | 19.98Cr | 19.75Cr | 17.47Cr | 8.43Cr | 7.42Cr | 7.38Cr | 6.69Cr | 7.82Cr | 9.92Cr | 10.13Cr | 19.75Cr | 13.87Cr |
| Enterprise value to EBITDA ratio | 12.29 | 10.61 | 29.93 | 19.88 | 15.63 | 25.97 | 26.78 | 33.91 | 17.02 | 7.02 | 7.22 | 7.39 | 5.39 | 23.83 | 5.16 | 8.65 | 11.25 |
| Debt to equity ratio | 0.17 | 0.14 | 0.18 | 0.16 | 0.15 | 0.24 | 0.27 | 0.26 | 0.29 | 0.22 | 0.43 | 0.69 | 0.65 | 0.73 | 0.56 | 0.57 | 0.43 |
| Return on equity % | 0 | 0.43 | 1.47 | 1.56 | 6.64 | 4.29 | 1.32 | 2.55 | -7.16 | 14.80 | 8.32 | 0.63 | 3.08 | -8.66 | 9.97 | 9.05 | 6.28 |
Beryl Drugs Ltd Enterprise Value
The Beryl Drugs Ltd Enterprise Value is a key financial metric used by investors to evaluate Beryl Drugs Ltd's valuation, profitability, and overall financial performance. Tracking the Beryl Drugs Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Beryl Drugs Ltd (NSE: , BSE: 524606) is currently trading at ₹24.92, with a market capitalization of ₹11.92Cr. As a leading company in the Health technology sector and Pharmaceuticals: other industry, monitoring the Beryl Drugs Ltd Enterprise Value is essential for fundamental analysis.
Beryl Drugs Ltd Enterprise Value Current Value
The current Beryl Drugs Ltd Enterprise Value stands at 13.87Cr.
The Beryl Drugs Ltd Enterprise Value has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Beryl Drugs Ltd Enterprise Value Historical Trend
The Beryl Drugs Ltd Enterprise Value has shown the following historical trend:
- 2025: 13.87Cr
- 2024: 19.75Cr
- 2023: 10.13Cr
- 2022: 9.92Cr
- 2021: 7.82Cr
The decline in Beryl Drugs Ltd Enterprise Value indicates improving financial efficiency or better earnings growth.
What Beryl Drugs Ltd Enterprise Value Indicates for Investors
The Beryl Drugs Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Beryl Drugs Ltd.
Beryl Drugs Ltd Enterprise Value Analysis Summary
The Beryl Drugs Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Beryl Drugs Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Beryl Drugs Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
